Optimal Management of Severe Asthma: A Roundtable Discussion

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes

Overview

This 60-minute DynamicCastTM webcast is a multi-faculty interactive presentation where pulmonary experts discuss the latest clinical data informing optimal care of patients with severe asthma, including guidance on identifying patients with severe asthma, initiating timely referrals, and accurately classifying asthma endotypes to guide treatment decisions. Participants will learn how to optimally integrate biologic therapies into the care of their patients with asthma along with using multidisciplinary care models to manage comorbidities, all in an effort to improve patient-centered care and overall patient outcomes. 

Learning Objectives

  1. Identify patients with severe asthma and initiate timely referral process to specialists to accurately diagnose and define asthma endotypes and optimize treatment plans.
  2. Provide accurate classification of asthma endotypes to guide treatment decisions with biologics.
  3. Apply multidisciplinary care models in the treatment of asthma and deliver patient-centered care.
  4. Manage comorbidities to improve treatment outcomes and patients’ quality of life.

Target Audience:

This educational initiative has been designed for asthma specialists (pulmonology and allergy/immunology) as well as primary care clinicians including MD, DO, APPs and Pharmacists.

 

This Evenings in Oncology enduring program is supported by independent medical educational grants from Regeneron Pharmaceuticals, Inc and Sanofi.

Presented By

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course opens: 
10/15/2024
Course expires: 
10/15/2025
Cost:
$0.00
Rating: 
0

Faculty

Laurie A. Manka, MD
Associate Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

 

Neil S. Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health – Abington
Philadelphia, PA

 

Eileen A. Wang, MD, MPH 
Associate Professor of Medicine
Division of Allergy & Immunology Clinical Services
National Jewish Health
University of Colorado
Aurora, CO

 

 

Conflict of Interest Disclosure Policy 

In accordance with the ACCME Standards for Commercial Support, Horizon CME must ensure balance, independence, objectivity, and scientific rigor. Prior to an activity, all faculty, authors, editors, and planning committee members participating in a Horizon CME activity are required to disclose to attendees any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Horizon CME has mitigated any conflicts of interest for this activity.

Faculty Disclosures

Laurie A. Manka, MD discloses that she is a consultant for CarelonRx.

Neil S. Skolnik, MD declares that he is a speaker for AstraZeneca, Lilly, GSK, Teva, Bayer and Heartland. He is also on advisory boards and serves as a consultant for AstraZeneca, Teva, Lilly, Sanofi, Sanofi Pasteur, GSK, Bayer, Abbot, and Novo Nordisk. Dr. Skolnik also conducts research for AstraZeneca, GSK, Novo Nordisk, and Novartis.

Eileen A. Wang, MD, MPH discloses that she is a speaker for AstraZeneca and Genentech as well as on an advisory board for AstraZeneca and GlaxoSmithKline. Dr. Wang conducts research for AstraZeneca, Genentech, GlaxoSmithKline and Sanofi.

Planners' and Managers Disclosures 

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Disclosure of Unlabeled Use 

Horizon CME requires that faculty participating in any continuing medical education (CME) to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer 

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above